Résumé
Objective To explore the efficacy and safety of rivaroxaban in the treatment of acute intermediate-risk pulmonary thromboembolism (PTE) complicated by deep vein thrombosis (DVT) of lower limbs.Methods The clinical data on 60 patients with acute intermediate-risk PTE with DVT of lower limbs who had been treated from January 2010 to March 2015 in Hunan Provincial People's Hospital were retrospectively analysed.60 patients were divided into rivaroxaban group and control group (low molecular heparin and sequential warfarin),30 in each group.Results Echocardiogrphy results showed that the right ventricular maximum short axis diameter,right to left ventricular maximum short axis diameter ratio and pulmonary artery systolic pressure significantly decreased,but the left ventricular maximum short axis diameter significantly increased after treatment on days 10,20,and 30 in rivaroxaban group and the control group,and there was no significant difference between the two groups (P ＞ 0.05 for all comparisons).NT-proBNP level was significantly reduced after treatment on days 10,20,and 30,whilePO2 value was significantly increased after treatment on days 10 and 20,and no statistical significance between the two groups (P ＞ 0.05 for all comparisons).D-dimer was obviously higher on day 10 and lower on days 20 and 30 in rivaroxaban group than that in the control group.Conclusions Treatment withrivaroxabanfor acute intermediate-risk PTE with DVT of lower limbs is effective and safe,worthy of clinical implementation and application.